PRESS RELEASEAbalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer--Dr. Marcus Kostka appointed CEO, Dr. Jörg Vollmer joins as CSO --Essen, Germany, October15, 2019–Abalos Therapeuticsannouncedtoday a EUR 12 million Series A financing roundestablishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strainthat preferentially infectsand proliferatesin cancer cellsgenerating a strong anti-tumor immune response.The Series A round was co-led by Boehringer Ingelheim Venture Fund(BIVF)and Gruenderfonds Ruhr, with participation from NRW.BANKandHigh-Tech Gruenderfonds(HTGF). Representatives from all investors will join the company’s newly formed Supervisory Board.Concurrent with the financing, Abalos announced the appointment of experienced entrepreneurs Dr. Marcus Kostka asChief Executive Officerand Dr. Jörg Vollmer asChief Scientific Officer. “Abalos’ goal is to capture the potent immune activation and highly specific tumor tropismof the arenavirus to propel a differentiated immuno-oncology approach towards clinical evaluation,” said Dr. Marcus Kostka, CEO of Abalos Therapeutics.“After funding and supporting a range of biotechnology companies over the years, this promising technology and the chanceto build a company with Jörg as a highly-experienced immunologyexpert made this opportunity extremely attractive.”The proceeds from the financing will be used to advanceAbalos’ arenavirus-based lead candidatestowards clinical testing. The Company will develop the initialproduct candidates using its proprietary Fast Evolution platform, whichwill generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability tore-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.The approach is basedonthe innovative research of immunologists Prof. Dr. Karl Lang, Chair of Immunology at the Medical Faculty, University Duisburg-Essenand Prof. Dr. Philipp Lang, Director of the Department of Molecular Medicine II, University Düsseldorf.Abalos builds on a close collaboration with the Universities Duisburg-Essen and Düsseldorf. Dr. Aristotelis Nastosfrom Gruenderfonds Ruhrcommented:“Immuno-oncology continues to make very exciting progress, however, developing drug candidates that can more fully harness the power of the immune system remains a challenge,in particular,addressing not only the main tumor but alsodistant metastases. We look forward to supporting Abalos’ experienced management team and its dedicated researchersto work on an arenavirus-based solution.”Dr. Marcus Kostka is a highlyseasoned industry expertbringing over 20 years and a range of experiences from Boehringer Ingelheim(BI), where he held positions defined by the ability to locate and advance innovation. Most recently, he wasVenture Fund Partnerat BI and held board positionsatseveral companies andparticipated in the successful exits of Rigontec and ICD Therapeutics.
In his role as CSO, Dr. Jörg Vollmer brings to Abalos Therapeutics significant knowledge and experience in the areas of immunology, oncology and infectious diseases, which he obtained in various R&D and executive positions over the course of his career. Most recently, Jörg was CSO at Rigontec where he helped advance a novel immuno-oncology treatment approach into the clinicandled the company’s R&D efforts until the acquisition by MSD in 2017. About AbalosAbalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake preciseinnate and adaptiveimmune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experiencedbiotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology. For more information, please visit www.abalos-tx.com.About Boehringer Ingelheim Corporate Venture Fund (BIVF)Operating as a separate legal entity, the Boehringer Ingelheim Corporate Venture Fund drives innovation through its strategic investments in early-stage science and technology. With an investment volume of 250 million euro, the Venture Fund invests in biotech and start-up companies with innovative concepts and technologies that have the potential to provide ground-breaking therapeutic platforms. The Venture Fund also creates companies when it identifies promising research projects in university and academia. The Venture Fund’s interest in young, mainly technology-oriented companies demonstrates its commitment to investigate new ideas and new science to prepare the way for Boehringer Ingelheim to expand into new therapeutic approaches and businesses. For more Information visit boehringer-ingelheim-venture.comAbout Gruenderfonds RuhrJointly initiated by Initiativkreis Ruhr and NRW.BANK, Gruenderfonds Ruhr is the first private-sector early-stage fund in the Ruhr region to be financed by regional industrial and financial companies. The fund invests in innovative and technology-oriented companies in the life science & health, digital economy, chemicals & new materials, energy & industry and logistics & trade sectors. Good growth and exit prospects as well as competent management are prerequisites. As a multi-corporate early-stage fundGruenderfonds Ruhralso opens up important industry access opportunities for the respective portfolio companies. www.gruenderfonds-ruhr.comAbout NRW BankNRW.BANK is the state development bank of North Rhine-Westphalia. Its mission is to support its owner –the state of North Rhine-Westphalia –in the completion of its structural and economic policy tasks. In its three fields of promotion “Economic Development”, “Housing Promotion” and “Infrastructure/Municipal Promotion”, NRW.BANK uses a wide range of promotion tools –from low-interest promotion loans to equity finance to advisory services. It cooperates with all banks and savings banks based in NRW on a competition-neutral basis. NRW.BANK takes into account the existing offers by the Federal Government, the North Rhine-Westphalian government and the European Union in the arrangement of its promotion. nrwbank.com
AboutHigh-Tech Gruenderfonds (HTGF)High-Tech Gruenderfonds(HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 550 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-techstartups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences. For more Information visit high-tech-gruenderfonds.deTo date, external investors have injected over EUR 2 billion into the HTGF portfolio via more than 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG. For more information, please contact: Abalos TherapeuticsGmbHMarcus Kostka, PhD, CEOPhone: +49 201 565787-00Email:firstname.lastname@example.orgAbalos media inquiries Trophic Communications Gretchen Schweitzer / Marie-Theresa WeickertTel: +49 89 2388 77-35 or+49 172 861 8540Email: email@example.com@trophic.eu